DelveInsight's Interleukin-23 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report ...

Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related disease presented at ...

Challenging six misconceptions that have characterized product strategies in Central and Eastern European markets.

Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related disease presented at EULAR 2025Additional orphan designation underscores Sanofi commitment to advancing ...

Detailed price information for Cellectar Biosciences Inc (CLRB-Q) from The Globe and Mail including charting and trades.

To navigate the post-LDC era successfully, Bangladesh must transition from a volume-driven, generics-dominated model to one ...

In August 2025, NexEos Diagnostics Inc . announced phase 2 study to assess the safety and exploratory diagnostic performance ...

Presented positive results from the phase 3 randomized, placebo-controlled clinical trial of CAN-2409 (aglatimagene ...

Ipsen has received approval from the European Commission (EC) for its Exelixis-partnered Cabometyx (cabozantinib) in advanced ...

A next-generation pneumococcal conjugate vaccine, PCV20, a single-dose protection is now available in India marking a new ...

The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted ...

A common painkiller can increase the risk of heart failure in older people, according to a major new study. It has sparked ...